A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
← catalyst calendarNCT06997029 · readout in 848 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
234estimated
Sites
21
Countries
Denmark, Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-01 | actual | When the study began enrolling |
| Primary completion | 2028-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Advanced Breast Cancer
- Advanced Ovarian Cancer
Interventions
- Drug: BMS-986500
- Drug: Palbociclib — also filed as IBRANCE®, PD 0332991
- Drug: Fulvestrant — also filed as FASLODEX®
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose Limiting Toxicities (DLTs)
measured Up to Day 28 From Last Dose
Number of Participants With Adverse Events (AEs)
measured Up to Day 28 From Last Dose
Number of Participants With Serious Adverse Events (SAEs)
measured Up to Day 28 From Last Dose
Number of Participants With AEs Leading to Discontinuation
measured Up to Day 28 From Last Dose
Number of Participants With TEAEs Leading to Death
measured Up to Day 28 From Last Dose
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed